Trace Amine-Associated Receptor 1 Agonist Modulates Mismatch Negativity-Like Responses in Mice.

RO5263397 TAAR1 event-related potentials mismatch negativity oddball paradigm schizophrenia biomarkers trace amine-associated receptors

Journal

Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923

Informations de publication

Date de publication:
2019
Historique:
received: 13 02 2019
accepted: 15 04 2019
entrez: 28 5 2019
pubmed: 28 5 2019
medline: 28 5 2019
Statut: epublish

Résumé

The trace amine-associated receptor 1 (TAAR1) is a G protein-coupled receptor widely expressed in the mammalian brain, particularly in limbic system and monoaminergic areas. It has proven to be an important modulator of dopaminergic, serotoninergic, and glutamatergic neurotransmission and is considered to be a potential useful target for the pharmacotherapy of neuropsychiatric disorders, including schizophrenia. One of the promising schizophrenia endophenotypes is a deficit in neurocognitive abilities manifested as mismatch negativity (MMN) deficit. This study examines the effect of TAAR1 partial agonist RO5263397 on the MMN-like response in freely moving C57BL/6 mice. Event-related potentials (ERPs) were recorded from awake mice in the oddball paradigm before and after RO5263397 administration. The RO5263397 (but not saline) administration increased the N40 amplitude in response to deviant stimuli. That provided the MMN-like difference at the 36-44 ms interval after the injection. The pitch deviance-elicited changes before the injection and in the control paradigm were established for the P68 component. After TAAR1 agonist administration the P68 amplitude in response both to standard and deviant stimuli was increased. These results suggest that the MMN-like response in mice may be modulated through TAAR1-dependent processes (possibly acting through the direct or indirect glutamate NMDA receptor modulation), indicating the TAAR1 agonists potential antipsychotic and pro-cognitive activity.

Identifiants

pubmed: 31130864
doi: 10.3389/fphar.2019.00470
pmc: PMC6509589
doi:

Types de publication

Journal Article

Langues

eng

Pagination

470

Références

Arch Gen Psychiatry. 2005 Feb;62(2):127-36
pubmed: 15699289
Acta Psychol (Amst). 1978 Jul;42(4):313-29
pubmed: 685709
Lancet. 1974 Jul 6;2(7871):52-3
pubmed: 4134443
Curr Opin Pharmacol. 2003 Feb;3(1):90-7
pubmed: 12550748
PLoS One. 2014 Oct 21;9(10):e110892
pubmed: 25333698
Brain Res. 2004 Sep 3;1019(1-2):189-200
pubmed: 15306253
Neuropsychopharmacology. 2001 Oct;25(4):498-504
pubmed: 11557163
Front Psychiatry. 2014 Aug 05;5:96
pubmed: 25140157
Biol Psychiatry. 1993 Apr 1;33(7):513-9
pubmed: 8513035
Psychopharmacology (Berl). 2007 Nov;194(4):443-51
pubmed: 17611739
Genes Brain Behav. 2007 Oct;6(7):628-39
pubmed: 17212650
Neuropharmacology. 2014 Jun;81:283-91
pubmed: 24565640
Psychopharmacology (Berl). 2002 Aug;163(1):42-53
pubmed: 12185399
Psychopharmacology (Berl). 1995 Sep;121(2):222-30
pubmed: 8545528
Brain Res Cogn Brain Res. 2001 Aug;12(1):109-16
pubmed: 11489614
Genomics. 2005 Mar;85(3):372-85
pubmed: 15718104
J Pharmacol Exp Ther. 2008 Mar;324(3):948-56
pubmed: 18083911
Int J Psychophysiol. 2015 Jun;96(3):134-40
pubmed: 25911953
J Neurosci Res. 2010 Jul;88(9):1962-9
pubmed: 20155805
Alcohol Clin Exp Res. 1995 Jun;19(3):607-10
pubmed: 7573781
Neuroimage. 2006 Jan 15;29(2):662-6
pubmed: 16112587
Pharmacol Biochem Behav. 1991 Apr;38(4):789-93
pubmed: 1831273
Psychophysiology. 1999 Sep;36(5):552-8
pubmed: 10442023
PLoS One. 2011;6(9):e24208
pubmed: 21915297
J Neurochem. 2011 Jan;116(2):164-76
pubmed: 21073468
J Affect Disord. 2001 Jan;62(1-2):93-100
pubmed: 11172876
Eur Neuropsychopharmacol. 2011 Dec;21(12):861-6
pubmed: 21470832
Pharmacol Ther. 2017 Dec;180:161-180
pubmed: 28723415
Brain Res. 2011 Jun 1;1393:91-9
pubmed: 21529784
Clin Neurophysiol. 2002 Dec;113(12):1894-902
pubmed: 12464326
Neurobiol Dis. 2015 Jan;73:289-95
pubmed: 25461194
Front Psychol. 2011 Dec 09;2:367
pubmed: 22180747
Ann N Y Acad Sci. 2015 May;1344:105-19
pubmed: 25752648
Biol Psychiatry. 1993 Feb 1;33(3):173-87
pubmed: 8383545
Psychiatry Res. 2005 Jan 30;138(1):61-74
pubmed: 15708302
Biol Psychol. 2016 Apr;116:28-35
pubmed: 26196895
Schizophr Bull. 2007 Jan;33(1):69-94
pubmed: 17135482
Front Psychol. 2011 Oct 28;2:283
pubmed: 22059082
Mol Psychiatry. 2013 May;18(5):543-56
pubmed: 22641180
Rev Recent Clin Trials. 2007 Jan;2(1):3-19
pubmed: 18473983
PLoS One. 2013 Dec 12;8(12):e82663
pubmed: 24349330
Neuropsychopharmacology. 2003 Apr;28(4):675-82
pubmed: 12655312
Arch Gen Psychiatry. 2005 Apr;62(4):371-8
pubmed: 15809404
Proc Natl Acad Sci U S A. 2011 May 17;108(20):8485-90
pubmed: 21525407
Neuropsychopharmacology. 2015 Aug;40(9):2217-27
pubmed: 25749299
Arch Gen Psychiatry. 2000 Dec;57(12):1139-47
pubmed: 11115327
Psychophysiology. 2009 Sep;46(5):1028-32
pubmed: 19497011
Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11962-7
pubmed: 8876245
Schizophr Res. 2018 Jan;191:43-50
pubmed: 28385587
Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):20081-6
pubmed: 19892733
J Cogn Neurosci. 2008 Aug;20(8):1403-14
pubmed: 18303985
J Psychopharmacol. 2000 Mar;14(1):21-9
pubmed: 10757249
Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):8966-71
pubmed: 11459929
Int J Neuropsychopharmacol. 2009 Feb;12(1):125-35
pubmed: 18771603
Mol Pharmacol. 2011 Sep;80(3):416-25
pubmed: 21670104
Neuropsychopharmacology. 2004 Apr;29(4):739-46
pubmed: 14735128
Prog Neurobiol. 2006 Aug;79(5-6):223-46
pubmed: 16962229
Neurotox Res. 2018 Oct;34(3):442-451
pubmed: 29713997
Brain Res. 2008 Apr 8;1203:97-102
pubmed: 18325485
Psychophysiology. 2011 Jan;48(1):4-22
pubmed: 20880261
Pharmacol Res. 2016 Jan;103:206-14
pubmed: 26640076
PLoS One. 2013 Apr 30;8(4):e63203
pubmed: 23646197
Int J Psychophysiol. 2001 Oct;42(2):177-94
pubmed: 11587775
Neuroimage. 2002 Aug;16(4):1052-61
pubmed: 12202092
Biol Psychol. 2006 Feb;71(2):123-47
pubmed: 15961210
Pharmacol Rev. 2018 Jul;70(3):549-620
pubmed: 29941461
Neuroreport. 2002 Jan 21;13(1):177-81
pubmed: 11924884
J Chromatogr. 1989 Apr 19;466:89-218
pubmed: 2663901

Auteurs

Aleksander A Aleksandrov (AA)

Department of Higher Nervous Activity and Psychophysiology, Saint Petersburg State University, Saint Petersburg, Russia.

Veronika M Knyazeva (VM)

Department of Higher Nervous Activity and Psychophysiology, Saint Petersburg State University, Saint Petersburg, Russia.

Anna B Volnova (AB)

Department of General Physiology, Saint Petersburg State University, Saint Petersburg, Russia.

Elena S Dmitrieva (ES)

Department of Higher Nervous Activity and Psychophysiology, Saint Petersburg State University, Saint Petersburg, Russia.

Nadezhda V Polyakova (NV)

Department of Higher Nervous Activity and Psychophysiology, Saint Petersburg State University, Saint Petersburg, Russia.

Raul R Gainetdinov (RR)

Institute of Translational Biomedicine and Saint Petersburg University Hospital, Saint Petersburg State University, Saint Petersburg, Russia.

Classifications MeSH